Facilitating the human connection in decentralized clinical trials
As a patient, I want to feel that I am in safe hands. I want to feel that the medical staff facing me know about my history, my needs, and how to address them. I want the same for my family and friends, and I believe every patient deserves this type of care and concern. This is true whether patients visit their regular health care provider, or whether they decide to volunteer in a traditional or decentralized clinical trial.
Clinical trial volunteers contribute to medical advances, sometimes without receiving any direct benefits. Without volunteers, clinical studies simply would not be possible. Based on my experience as a clinical research coordinator and now as a clinical writer at ScienceMedia, I want to help ensure that the doctors, researchers, and clinical staff interacting with trial participants are well knowledgeable about the trial they are conducting so that they also have the confidence to effectively address the participants' needs and concerns.
This is especially important in decentralized clinical trials where many of the trial participant touchpoints occur through remote monitoring. In this type of patient-centric approach, although participants do not get to meet the study staff in person, the human connection is still one of the most important aspects of the patient's experience. The trust and rapport established through telemedicine encounters lay the groundwork for effective patient's engagement throughout the decentralized clinical trial. Even through a screen, participants need to feel that the study team is well trained, abreast of any safety issues, and aware of their needs.
As a clinical writer, I see my role as helping facilitate the human connection in clinical trials, whether they are decentralized or on-site. By translating text-heavy clinical documents into impactful, interactive, educational content that the study team can review at their own peace, we help build strong expertise among the clinical team and ultimately create meaningful prolific human interactions.
As a Clinical Writer at ScienceMedia since July 2020, Claire has focused on all aspects of clinical trial training, including risk mitigation and patient safety, for SMi Trial and SMi TrialD. She has experience in clinical and fundamental research, teaching, and volunteering in public health projects. Prior to joining ScienceMedia, Claire served as a Clinical Research Coordinator for a pediatric clinical trial at the University of California San Diego. She previously conducted research at Scripps Research in the area of metabolism in relation to cancer, obesity, and diabetes. Claire holds a Ph.D. in Molecular and Cellular Pharmacology from Paul Sabatier University, Toulouse, France.
This all comes down to understanding the specific needs of that specific community, and none of us are the same. It's not always a one-size-fits-all. - Jocelyn Ashford on defining success in promoting health equity in clinical trials
The ultimate measure of success to me would be that we no longer need to focus specifically on this idea of diversity. It should automatically be embedded in everything that we do. - Jocelyn Ashford on defining success in promoting health equity in clinical trials
For moviegoers, Morpheus' line, "Unfortunately, no one can be told what the Matrix is. You have to see it for yourself," followed by an offering of a red or blue pill to Neo, brings us right to the scene in the mega blockbuster hit, The Matrix.
As we reflect on this past year, let's close out 2023 by acknowledging the great strides pharma has made. Who's on board for some levity? If you are, read on.
Clinical trials are a crucial part of the medical research process for all patient communities. These trials help researchers determine the safety and effectiveness of new treatments and drugs, as well as identify potential side effects and other factors that may affect patients' health and wellbeing. However, conducting clinical trials for rare diseases comes with a unique set of challenges that can make the process more difficult and complex than trials for more common diseases.
The clinical research community is continually called to modernize its approach to clinical trials. More recently, this push is attributed to the passing of the Food and Drug Omnibus Reform Act (FDORA), intended to reshape clinical trial design and operations.
ScienceMedia and Halloran Consulting Group (Halloran) recently collaborated during a Halloran-hosted CORE Retreat - a Clinical Operations Retreat for Executives - in the Boston area. The connection between these companies is simple. They understand the proven need to provide results-driven and multi-media format training to sponsors operating clinical trials across all phases of the study.
Halloran Consulting Group launched CORE East over two decades ago - a Clinical Operations Retreat for Executives - which is an invitation-only meeting that brings together an exclusive group of senior leaders in clinical development to discuss and debate the most pressing issues around the business of product development and building enduring life science companies.
To use a sports analogy, protocol deviations and violations in a clinical study represent unforced errors. The application of proper study training, like that delivered through SMi TrialTM, ScienceMedia's Protocol Compliance Management platform, has been proven to reduce and eliminate these entirely avoidable mistakes.
Decentralized Clinical Trials (DCTs), and their near cousins that apply a hybrid approach of in-person and remote visits, are increasingly seen as a viable solution for the conduct of clinical trials.
Facilitating the human connection in decentralized clinical trials
Evaluating potential technological barriers among participants can help to improve study outcomes
My journey from participating in a trial, to supporting them.
Over the last four years at ScienceMedia, I have worked with dozens of study teams to understand the unique operational complexities of their clinical trials.
